Literature DB >> 16494641

Rapid onset of effect of sodium alginate on gastro-oesophageal reflux compared with ranitidine and omeprazole, and relationship between symptoms and reflux episodes.

P W Dettmar1, J Sykes, S L Little, J Bryan.   

Abstract

The objective of the open, randomised, four-period crossover study was to compare the time of onset of effect of sodium alginate (SA), omeprazole, ranitidine and control, based on oesophageal and intragastric pH and to determine any correlation between reflux symptoms and episodes in volunteers suffering from occasional gastro-oesophageal reflux. SA showed extensive prevention of acid exposure in the oesophagus compared with other treatments during the first hour. Overall, SA was more effective than control or omeprazole and comparable with ranitidine. There was little evidence of association between 'oesophageal' symptoms and reflux episodes, but associations between 'gastric' symptoms and acidity in the oesophagus, fundus and corpus were apparent. For an immediate reduction in gastro-oesophageal reflux into the oesophagus and gastric acidity during the first hour, SA was significantly superior to control, ranitidine and omeprazole. Ranitidine showed a superior effect from 2 h, consistent with its pharmacological mode of action.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16494641     DOI: 10.1111/j.1368-5031.2006.00800.x

Source DB:  PubMed          Journal:  Int J Clin Pract        ISSN: 1368-5031            Impact factor:   2.503


  9 in total

Review 1.  Recent Advances in the Pharmacological Management of Gastroesophageal Reflux Disease.

Authors:  Yu-Min Kung; Wen-Hung Hsu; Meng-Chieh Wu; Jiunn-Wei Wang; Chung-Jung Liu; Yu-Chung Su; Chao-Hung Kuo; Fu-Chen Kuo; Deng-Chyang Wu; Yao-Kuang Wang
Journal:  Dig Dis Sci       Date:  2017-11-06       Impact factor: 3.199

2.  Alginates: From the ocean to gastroesophageal reflux disease treatment.

Authors:  Serhat Bor; İsmail Hakkı Kalkan; Altay Çelebi; Dinç Dinçer; Filiz Akyüz; Peter Dettmar; Hasan Özen
Journal:  Turk J Gastroenterol       Date:  2019-09       Impact factor: 1.852

3.  Sodium alginate ameliorates indomethacin-induced gastrointestinal mucosal injury via inhibiting translocation in rats.

Authors:  Atsuki Yamamoto; Tomokazu Itoh; Reishi Nasu; Ryuichi Nishida
Journal:  World J Gastroenterol       Date:  2014-03-14       Impact factor: 5.742

4.  Early onset of efficacy in patients with functional and motility-related gastrointestinal disorders : A noninterventional study with Iberogast®.

Authors:  Richard Raedsch; Bettina Vinson; Bertram Ottillinger; Gerald Holtmann
Journal:  Wien Med Wochenschr       Date:  2017-07-25

5.  Randomised clinical trial: the effectiveness of Gaviscon Advance vs non-alginate antacid in suppression of acid pocket and post-prandial reflux in obese individuals after late-night supper.

Authors:  Mohd Adli Deraman; Muhammad Ilham Abdul Hafidz; Rona Marie Lawenko; Zheng Feei Ma; Mung Seong Wong; Cathal Coyle; Yeong Yeh Lee
Journal:  Aliment Pharmacol Ther       Date:  2020-04-28       Impact factor: 8.171

6.  Alternative vs. conventional treatment given on-demand for gastroesophageal reflux disease: a randomised controlled trial.

Authors:  Per G Farup; Mathis Heibert; Victor Høeg
Journal:  BMC Complement Altern Med       Date:  2009-02-24       Impact factor: 3.659

7.  Alginate as a protease inhibitor in vitro and in a model gut system; selective inhibition of pepsin but not trypsin.

Authors:  Peter Ian Chater; Mathew D Wilcox; Iain A Brownlee; Jeffrey P Pearson
Journal:  Carbohydr Polym       Date:  2015-06-04       Impact factor: 9.381

8.  Current pharmacological management of gastroesophageal reflux disease.

Authors:  Yao-Kuang Wang; Wen-Hung Hsu; Sophie S W Wang; Chien-Yu Lu; Fu-Chen Kuo; Yu-Chung Su; Sheau-Fang Yang; Chiao-Yun Chen; Deng-Chyang Wu; Chao-Hung Kuo
Journal:  Gastroenterol Res Pract       Date:  2013-06-26       Impact factor: 2.260

9.  Randomised clinical trial: the clinical efficacy and safety of an alginate-antacid (Gaviscon Double Action) versus placebo, for decreasing upper gastrointestinal symptoms in symptomatic gastroesophageal reflux disease (GERD) in China.

Authors:  J Sun; C Yang; H Zhao; P Zheng; J Wilkinson; B Ng; Y Yuan
Journal:  Aliment Pharmacol Ther       Date:  2015-07-31       Impact factor: 8.171

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.